These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 25737147)

  • 1. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.
    Asín-Prieto E; Rodríguez-Gascón A; Isla A
    J Infect Chemother; 2015 May; 21(5):319-29. PubMed ID: 25737147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimisation of antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles.
    Hoo GSR; Liew YX; Kwa AL
    Indian J Med Microbiol; 2017; 35(3):340-346. PubMed ID: 29063877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
    Preston SL
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
    Mouton JW; Ambrose PG; Canton R; Drusano GL; Harbarth S; MacGowan A; Theuretzbacher U; Turnidge J
    Drug Resist Updat; 2011 Apr; 14(2):107-17. PubMed ID: 21440486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.
    Abdul-Aziz MH; Lipman J; Mouton JW; Hope WW; Roberts JA
    Semin Respir Crit Care Med; 2015 Feb; 36(1):136-53. PubMed ID: 25643277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic/pharmacodynamic analysis in microbiology: a tool for the evaluation of the antimicrobial treatment].
    Canut Blasco A; Aguilar Alfaro L; Cobo Reinoso J; Giménez Mestre MJ; Rodríguez-Gascón A
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):48-57. PubMed ID: 23850188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.
    Zhao M; Lepak AJ; Andes DR
    Bioorg Med Chem; 2016 Dec; 24(24):6390-6400. PubMed ID: 27887963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.
    Roberts JA; Kirkpatrick CM; Lipman J
    J Antimicrob Chemother; 2011 Feb; 66(2):227-31. PubMed ID: 21118912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Chua HC; Tse A; Smith NM; Mergenhagen KA; Cha R; Tsuji BT
    Int J Antimicrob Agents; 2021 Mar; 57(3):106269. PubMed ID: 33358761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Guidance for Antibiotic Dosing in Obese Adults.
    Meng L; Mui E; Holubar MK; Deresinski SC
    Pharmacotherapy; 2017 Nov; 37(11):1415-1431. PubMed ID: 28869666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.
    de Velde F; Mouton JW; de Winter BCM; van Gelder T; Koch BCP
    Pharmacol Res; 2018 Aug; 134():280-288. PubMed ID: 30033398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
    Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
    Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.